Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies

Table 2 Summary of studies investigating the chemopreventive effect of sulfasalazine and 5-ASA therapies in ulcerative colitis

Study	Study design	n	Drug studies	Principal outcome
Pinczowski et al[31]	Case-control	298	Sulfasalazine > 3 mo	ORCRC: 0.38 (95% CI, 0.2-0.69) patients administered sulfasalazine
Moody et al[101]	Case-control	175	Sulfasalazine < 6 mo	10-fold elevated risk in non-exposed patients (30% vs 3%)
Eaden et al[40]	Case-control	102	Sulfasalazine, mesalasine regular use	ORCRC: 0.25 (95% CI, 0.13-0.48) in regular users
Lindberg et al[102]	Cohort study	143	Sulfasalazine > 6 mo	Non-significant decrease of risk (34% vs 44%)
Bernstein et al[87]	Case-control	373	5-ASA	Non-significant elevation of risk in patients exposed
Rutter et al[29]	Case-control	204	5-ASA	Non-significant elevation of risk of dysplasia in patients exposed
Rubin et al[90]	Case-control	124	5-ASA > 1.2 g regular use	ORCRC: 0.28 (95% CI, 0.09-0.85) in regular users